A prospective randomized controlled study comparing continuing treatment with an anti-TNF antibody (infliximab) and an antimetabolite to contiuing with a single agent, either with the anti-TNF antibody or the anti-metabolite in Crohn’s disease in patients without clinical sympthoms and without steroids on combination therapy A prospective randomized controlled study comparing continuing treatment with an anti-TNF antibody ( ...
A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy to anti-metabolites monotheRapy and infliximab monothErapy in Crohn’s disease patients in sustained steroid-free remission on combination therapy A proSpective randomized controlled trial comParing infliximAb-antimetabolites combination therapy t ...
Crohn´s disease;Therapeutic area: Diseases [C] - Digestive System Diseases [C06]